Amgen Weighs In to Chase Rival Obesity Drugs From Novo Nordisk and Eli Lilly
An Amgen drug led to weight loss that was sustained, clinical data that support advancing the molecule to a Phase 2 test expected to start in early 2023. While AMG 133 trails rival products from Novo Nordisk and Eli Lilly, Amgen hopes to offer patients a dosing edge.
Source: medcitynews.com